Predictors of In-Stent Stenosis Following the Implantation of Pipeline Embolization Devices for the Treatment of Aneurysms Located at or beyond the Circle of Willis in the Anterior Circulation

References

1. 1.↵
   2. Hanel RA,
   3. Kallmes DF,
   4. Lopes DK, et al

   . Prospective study on embolization of intracranial aneurysms with the Pipeline device: the PREMIER study 1 year results. J Neurointerv Surg 2020;12:62–66 doi:10.1136/neurintsurg-2019-015091 pmid:31308197

   Abstract/FREE Full Text
2. 2.↵
   2. Becske T,
   3. Kallmes DF,
   4. Saatci I, et al

   . Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology 2013;267:858–68 doi:10.1148/radiol.13120099 pmid:23418004

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Yavuz K,
   3. Geyik S,
   4. Saatci I, et al

   . Endovascular treatment of middle cerebral artery aneurysms with flow modification with the use of the Pipeline Embolization Device. AJNR Am J Neuroradiol 2014;35:529–35 doi:10.3174/ajnr.A3692 pmid:24072620

   Abstract/FREE Full Text
4. 4.↵
   2. Primiani CT,
   3. Ren Z,
   4. Kan P, et al

   . A2, M2, P2 aneurysms and beyond: results of treatment with Pipeline Embolization Device in 65 patients. J Neurointerv Surg 2019;11:903–07 doi:10.1136/neurintsurg-2018-014631 pmid:30674637

   Abstract/FREE Full Text
5. 5.↵
   2. Pistocchi S,
   3. Blanc R,
   4. Bartolini B, et al

   . Flow diverters at and beyond the level of the circle of Willis for the treatment of intracranial aneurysms. Stroke 2012;43:1032–38 doi:10.1161/STROKEAHA.111.636019 pmid:22282890

   Abstract/FREE Full Text
6. 6.↵
   2. Martínez-Galdámez M,
   3. Romance A,
   4. Vega P, et al

   . Pipeline Endovascular Device for the treatment of intracranial aneurysms at the level of the circle of Willis and beyond: multicenter experience. J Neurointerv Surg 2015;7:816–23 doi:10.1136/neurintsurg-2014-011355 pmid:25200247

   Abstract/FREE Full Text
7. 7.↵
   2. Lin N,
   3. Lanzino G,
   4. Lopes DK, et al

   . Treatment of distal anterior circulation aneurysms with the Pipeline Embolization Device: a US multicenter experience. Neurosurgery 2016;79:14–22 doi:10.1227/NEU.0000000000001117 pmid:26579967

   CrossRefPubMed
8. 8.↵
   2. Martin AR,
   3. Cruz JP,
   4. O’Kelly C, et al

   . Small pipes: preliminary experience with 3-mm or smaller Pipeline flow-diverting stents for aneurysm repair prior to regulatory approval. AJNR Am J Neuroradiol 2015;36:557–61 doi:10.3174/ajnr.A4170 pmid:25395659

   Abstract/FREE Full Text
9. 9.↵
   2. Liou TM,
   3. Li YC

   . Effects of stent porosity on hemodynamics in a sidewall aneurysm model. J Biomech 2008;41:1174–83 doi:10.1016/j.jbiomech.2008.01.025 pmid:18377914

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Turhon M,
    3. Kang H,
    4. Liu J, et al

    . In-stent stenosis after Pipeline Embolization Device in intracranial aneurysms: incidence, predictors, and clinical outcomes. Neurosurgery 2022;91:943–51 doi:10.1227/neu.0000000000002142 pmid:36129281

    CrossRefPubMed
11. 11.↵
    2. Wei D,
    3. Deng D,
    4. Gui S, et al

    . Machine learning to predict in-stent stenosis after Pipeline Embolization Device placement. Front Neurol 2022;13:92984 doi:10.3389/fneur.2022.912984 pmid:3614704]4

    CrossRefPubMed
12. 12.↵
    2. O’Kelly CJ,
    3. Krings T,
    4. Fiorella D, et al

    . A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol 2010;16:133–37 doi:10.1177/159101991001600204 pmid:20642887

    CrossRefPubMed
13. 13.↵
    2. Park K,
    3. Ahn CW,
    4. Lee SB, et al

    . Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care 2019;42:1569–73 doi:10.2337/dc18-1920 pmid:31182490

    Abstract/FREE Full Text
14. 14.↵
    2. John S,
    3. Bain MD,
    4. Hui FK, et al

    . Long-term follow-up of in-stent stenosis after Pipeline flow diversion treatment of intracranial aneurysms. Neurosurgery 2016;78:862–67 doi:10.1227/NEU.0000000000001146 pmid:26600281

    CrossRefPubMed
15. 15.↵
    2. Tian X,
    3. Chen S,
    4. Zhang Y, et al

    . Time course of the triglyceride glucose index accumulation with the risk of cardiovascular disease and all-cause mortality. Cardiovasc Diabetol 2022;21:183 doi:10.1186/s12933-022-01617-2 pmid:36100896

    CrossRefPubMed
16. 16.↵
    2. Luo E,
    3. Wang D,
    4. Yan G, et al

    . High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol 2019;18:150 doi:10.1186/s12933-019-0957-3 pmid:31722708

    CrossRefPubMed
17. 17.↵
    2. Guo X,
    3. Shen R,
    4. Yan S, et al

    . Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention. Cardiovasc Diabetol 2023;22:43 doi:10.1186/s12933-023-01779-7 pmid:36864455

    CrossRefPubMed
18. 18.↵
    2. Ding X,
    3. Wang X,
    4. Wu J, et al

    . Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol 2021;20:76 doi:10.1186/s12933-021-01268-9 pmid:33812373

    CrossRefPubMed
19. 19.↵
    2. Wang A,
    3. Wang G,
    4. Liu Q, et al

    . Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up. Cardiovasc Diabetol 2021;20:46 doi:10.1186/s12933-021-01238-1 pmid:33602208

    CrossRefPubMed
20. 20.↵
    2. Kim J,
    3. Montagnani M,
    4. Koh KK, et al

    . Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888–904 doi:10.1161/CIRCULATIONAHA.105.563213 pmid:16618833

    Abstract/FREE Full Text
21. 21.↵
    2. Kamata H,
    3. Honda SI,
    4. Maeda S, et al

    . Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649–61 doi:10.1016/j.cell.2004.12.041 pmid:15766528

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Savage DB,
    3. Petersen KF,
    4. Shulman GI

    . Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005;45:828–33 doi:10.1161/01.HYP.0000163475.04421.e4 pmid:15824195

    CrossRefPubMed
23. 23.↵
    2. Lowell BB,
    3. Shulman GI

    . Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384–87 doi:10.1126/science.1104343 pmid:15662004

    Abstract/FREE Full Text
24. 24.↵
    2. Zeng G,
    3. Nystrom FH,
    4. Ravichandran LV, et al

    . Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539–45 doi:10.1161/01.cir.101.13.1539 pmid:10747347

    Abstract/FREE Full Text
25. 25.↵
    2. Breen DM,
    3. Chan KK,
    4. Dhaliwall JK, et al

    . Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol 2009;29:1060–66 doi:10.1161/ATVBAHA.109.185447 pmid:19359661

    Abstract/FREE Full Text
26. 26.↵
    2. Salt IP,
    3. Morrow VA,
    4. Brandie FM, et al

    . High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem 2003;278:18791–97 doi:10.1074/jbc.M210618200 pmid:12644458

    Abstract/FREE Full Text
27. 27.↵
    2. Sweid A,
    3. Starke RM,
    4. Herial N, et al

    . Predictors of complications, functional outcome, and morbidity in a large cohort treated with flow diversion. Neurosurgery 2020;87:730–43 doi:10.1093/neuros/nyz508 pmid:31858148

    CrossRefPubMed
28. 28.↵
    2. Simoncini T,
    3. Hafezi-Moghadam A,
    4. Brazil DP, et al

    . Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538–41 doi:10.1038/35035131 pmid:11029009

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Gui S,
    3. Chen X,
    4. Wei D, et al

    . Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline embolization device treatment of intracranial aneurysms. J Neurointerv Surg 2023;15:1187–93 doi:10.1136/jnis-2022-019680 pmid:36690440

    Abstract/FREE Full Text
30. 30.↵
    2. Monteiro A,
    3. Lopes DK,
    4. Aghaebrahim A, et al

    . Optical coherence tomography for elucidation of flow-diversion phenomena: the concept of endothelized mural thrombus behind reversible in-stent stenosis in flow-diverters. Interv Neuroradiol 2021;27:774–80 doi:10.1177/15910199211003432 pmid:33752477

    CrossRefPubMed
31. 31.↵
    2. Sindeev S,
    3. Prothmann S,
    4. Frolov S, et al

    . Intimal hyperplasia after aneurysm treatment by flow diversion. World Neurosurg 2019;122:e577–83 doi:10.1016/j.wneu.2018.10.107 pmid:31108073

    CrossRefPubMed